AlphAIAlphAI — Financial news for AI agents
SEC EDGARJUN 21 min read$GLUE

Warmuth Markus sold $106K of GLUE

Warmuth Markus (President & CEO) sold 5,466 shares of Monte Rosa Therapeutics, Inc. (GLUE) at an average of $19.44 ($19.41–$19.73, $0.11M total) across 2 trades on 2026-06-01 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Warmuth Markus
Published Jun 2, 2026, 8:05 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 28, 2026, 3:47 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$GLUE
Bearish
high confidence
Mentioned
$GLUE
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$GLUEBearishLow
01

Why it matters

The disclosure is a primary source filing; the transaction size is modest, likely causing limited price movement.

02

Market read

First‑report insider sale; modest impact on GLUE's share price.

03

What to watch

Insider retains a large stake, suggesting continued confidence despite the sale.

Relevance 3/10Novelty 3/10Timing: after‑hours filing

Background

Monte Rosa Therapeutics (GLUE) filed a Form 4 reporting a $106K insider sale by its CEO under a pre‑arranged 10b5‑1 plan.

Company-level read

Ticker impact

$GLUEBearishHigh confidence
Context

President & CEO Warmuth Markus sold 5,466 shares for $106K via a 10b5‑1 plan, reducing his stake to 594,538 shares.

Expected impact

likely modest downward pressure as market prices in insider sale

Evidence & confidence

Form 4 filing is the first public disclosure of the sale; the amount is small relative to float, so impact is limited.

Market effects

Sector

No broader sector impact; typical insider sale in biotech.

Regional

U.S. market only.

Global

Limited to Monte Rosa investors.

Counterpoint

What could challenge this read

The sale may be routine and not indicative of future performance; investors could view it as neutral.

Key entities

  • company
    Monte Rosa Therapeutics, Inc.

    Biotech company listed on Nasdaq under ticker GLUE.

  • person
    Warmuth Markus

    President & CEO of Monte Rosa Therapeutics.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

GLUE insider trading history →

Related articles

OCT 11
$GLUEMed

Monte Rosa Therapeutics assumed with a Buy at UBS

UBS initiated coverage of Monte Rosa Therapeutics (GLUE) with a Buy rating and $19 price target, citing the potential of its drug MRT-8102 for chronic inflammatory diseases. The firm highlights the drug's differentiated profile and the company's atherosclerotic cardiovascular disease opportunity.

tipranks.com1 min
OCT 5
$GLUEMedAI 8/10

H.C. Wainwright reiterates Monte Rosa stock rating on trial data

H.C. Wainwright reiterated a Buy rating and $25.00 price target on Monte Rosa Therapeutics (GLUE) after positive clinical trial results for MRT-8102. The stock is currently trading at $10.50, down 10% over the past week. Jefferies also raised its price target to $40, maintaining a Buy rating. The company is conducting a phase 2 study for metastatic prostate cancer and expects further clinical data catalysts in 2026 and 2027.

investing.com2 min
OCT 3
$GLUEMedAI 8/10

Monte Rosa Therapeutics Stock In Focus After Phase 1 Data Win

Monte Rosa Therapeutics reported positive Phase 1 results for MRT-8102, showing significant biomarker reductions and no serious adverse events. The data supports its planned Phase 2b study in coronary artery disease. The company forecasts revenue of $88.1M and earnings of $15.2M by 2029, with current losses of $161.1M and revenue of $28.7M.

simplywall.st2 min
OCT 1
$GLUEMedAI 8/10

Monte Rosa's MRT-8102 Drives 80%-90% NEK7 Degradation In Phase 1

Monte Rosa Therapeutics (GLUE) reported Phase 1 results showing MRT-8102 achieved 80%-90% NEK7 degradation, reducing biomarkers linked to cardiovascular disease. The treatment was well-tolerated with no serious adverse events. GLUE plans Phase 2 trials in 2026-2027 for coronary artery disease, gout, and hidradenitis suppurativa. GLUE stock is currently down 5.74% at $11.24.

rttnews.com2 min